2/7/2020 | CV | Market Commentary: Morning Commentary: Smart Global convertible notes expand on debut; Assertio in focus
|
8/29/2018 | CV | Market Commentary: Convertibles trading light; ServiceNow, Unisys reach new heights; Depomed notes active
|
7/31/2018 | BKCACV | S&P downgrades Depomed
|
7/10/2018 | CV | Market Commentary: Sempra on tap; Palo Alto’s $1.5 billion deal hits the market; Depomed up on the week
|
12/14/2017 | BKCACV | S&P changes Depomed view
|
12/6/2017 | CV | Market Commentary: Granite Point talks new deal; Cleveland-Cliffs tops par; pharmaceutical names eyed
|
12/5/2017 | CV | Market Commentary: Market awaits Cleveland Cliffs issue, Depomed on the rise, General Cable in demand
|
10/26/2017 | CV | Market Commentary: Weibo jumps; China Lodging on tap; Depomed eyed as Trump takes aim at ‘opioid crisis’
|
10/17/2017 | CV | Market Commentary: Impax Laboratories jumps in active trade after merger news; Herbalife slips; Cemex up
|
8/8/2017 | CV | Market Commentary: BioMarin paper wanes in wake of new issue; Blackstone dips on add-on; Depomed tanks
|
7/13/2017 | BKCACV | S&P rates Depomed loan BB-, convertibles B-
|
5/10/2017 | CV | Market Commentary: Depomed convertible notes recover from day’s lows; Vitamin Shoppe loses ground
|
5/10/2017 | CV | Market Commentary: Morning Commentary: Depomed convertibles weaken on wider loss; Dermira, Becton deals on deck
|
4/4/2017 | CV | Market Commentary: Acorda convertibles under pressure; Depomed edges up on debt payment; Gogo goes up
|
4/4/2017 | CV | Market Commentary: Morning Commentary: Acorda Therapeutics convertibles under pressure; Depomed edges up on payment
|
2/22/2017 | CV | Market Commentary: Parker Drilling’s new preferreds fizzle; fresh earnings drive movement in DISH, Tesla
|
11/8/2016 | CV | Market Commentary: Priceline convertibles rise on earnings beat; Depomed misses; Medicines mixed; Iconix steady
|
11/8/2016 | CV | Market Commentary: Morning Commentary: Priceline convertibles rise on earnings beat; Depomed misses; Medicines mixed
|
11/3/2016 | CV | Market Commentary: Depomed convertible bonds lose ground amid takeover talk; election eyed; Dynegy recovers
|
11/3/2016 | CV | Market Commentary: Morning Commentary: Depomed convertible bonds lose ground amid takeover talk; election still eyed
|
10/4/2016 | CV | Market Commentary: Depomed on radar in wake of patent suit win; NXP still active; NQ Mobile settles placement
|
10/4/2016 | CV | Market Commentary: Morning Commentary: Depomed remains on radar; NXP notes still active; NQ Mobile settles placement
|
10/3/2016 | CV | Market Commentary: Ship Finance new issue steady; Depomed better on patent suit win; Tesla convertibles firm
|
10/3/2016 | CV | Market Commentary: Morning Commentary: Ship Finance new issue steady; Depomed busy on patent suit win; Tesla rises
|
9/19/2016 | CV | Market Commentary: Morning Commentary: DepoMed’s convertibles trade just under 140; PTC Therapeutics poised to move up
|
5/9/2016 | CV | Market Commentary: Teva makes outright gains after positive earnings; Illumina flat as health care rallies
|
4/13/2016 | CV | Market Commentary: Health care convertibles mixed; energy ‘trickles back’; China-related names active on data
|
4/12/2016 | CV | Market Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake extends gains
|
4/12/2016 | CV | Market Commentary: Morning Commentary: Horizon Pharma drops; Clovis in focus; Anacor, Depomed slip; Chesapeake gains
|
4/8/2016 | CV | Market Commentary: Depomed surges after activist letter to the board; Yahoo! richens on deal chatter
|
4/8/2016 | CV | Market Commentary: Morning Commentary: Depomed surges in active trade after activist letter to the board
|
4/7/2016 | CV | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
3/15/2016 | CV | Market Commentary: Valeant woes cast a pall over convertible biotech/health care; energy shows resilience
|
1/11/2016 | CV | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
1/11/2016 | CV | Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
|
10/23/2015 | CV | Market Commentary: Huron slides outright, ‘comes in’ on swap on disappointing earnings; Horizon rebounds
|
9/22/2015 | CV | Market Commentary: Convertibles, broader markets drop; Weatherford deal pulled, stock rebounds; biotechs down
|
7/20/2015 | CV | Market Commentary: Exelixis jumps outright, expands on hedge on positive trial data; Depomed better on hedge
|
7/7/2015 | CV | Market Commentary: Medicines higher in active trade; Depomed deflects Horizon offer; Ctrip off its lows
|
7/7/2015 | CV | Market Commentary: Morning Commentary: Medicines convertibles higher in active trade; Depomed deflects Horizon offer
|
5/12/2015 | CV | Market Commentary: Planned SunEdison seen cheap; existing SunEdisons finish unchanged; Depomed drops outright
|
5/12/2015 | CV | Market Commentary: Morning Commentary: Planned SunEdison looks cheap; existing SunEdisons in focus; Depomed lower
|
4/9/2015 | CV | Market Commentary: Qihoo, other Asian internet names up again in active trade; Isis improves; Teva at parity
|
3/13/2015 | CV | Market Commentary: FXCM bumps up on positive earnings; Herbalife adds outright, unchanged dollar neutral
|
2/24/2015 | CV | Market Commentary: Morning Commentary: American Tower on tap with $1.25 billion mandatory; secondary softens
|
9/9/2014 | CV | Market Commentary: Convertibles mixed to weaker; Yahoo! lower outright, on hedge; Molina mixed; Herbalife up
|
9/9/2014 | CV | Depomed greenshoe exercise lifts convertible sale to $345 million
|
9/9/2014 | CV | Market Commentary: Morning Commentary: Yahoo convertibles move lower outright, on hedge; Depomed adds
|
9/5/2014 | CV | Market Commentary: New Huron Consulting trades at par; Depomed shares push higher after court decision
|
9/5/2014 | CV | Market Commentary: Morning Commentary: New Huron trades around issue price; Depomed slips with shares
|
9/4/2014 | CV | Market Commentary: New Clovis, Depomed upsized, add on debut; Electronics For Imaging edges up; Teslas mixed
|
9/4/2014 | CV | Market Commentary: Morning Commentary: Clovis, Depomed add with underlying shares mixed; Electronics For Imaging gains
|
9/4/2014 | CV | New Issue: Depomed sells upsized $300 million seven-year convertibles to yield 2.5%, up 37%
|
9/3/2014 | CV | Market Commentary: Planned Depomed, Electronics For Imaging add in the gray; Huron Consulting notes on tap
|
9/3/2014 | CV | Market Commentary: Morning Commentary: New deals in focus; Clovis Oncology shares sharply lower; Exelixis slips
|
9/2/2014 | CV | Market Commentary: Endo, Gilead weaker; primary market sees Electronics For Imaging, Depomed, Clovis on tap
|
9/2/2014 | CV | Depomed plans $230 million seven-year convertibles to yield 2.625%-3.125%, up 30%-35%
|
5/25/2012 | CVHYPF | Depomed files $100 million shelf covering stock, debt and preferreds
|
12/31/2008 | CVHY | Depomed files $100 million shelf registration
|
12/20/2005 | BTCV | Depomed files $100 million shelf
|